Episode Description: What do the latest METEOROID trial results mean for neurologists treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD)? Michael Levy, MD, Massachusetts General Hospital, Boston, MA, discusses relapse prevention, diagnostic challenges, and the future of MOGAD management with Peter Sguigna, MD, UT Southwestern Medical Center, Dallas, TX.
Podzilla Summary coming soon
Sign up to get notified when the full AI-powered summary is ready.
Free forever for up to 3 podcasts. No credit card required.
Listen to This Episode
More from NeuroFrontiers
Can We Delay Alzheimer's Symptoms Before They Begin? Inside the PrevenTRON Trial
Subcutaneous Lecanemab for Early Alzheimer Disease: Evidence, Safety, and Patient Selection
Next-Generation CNS Drug Delivery: Brainshuttle Technology and Clinical Implications in Alzheimer Disease
Generalized Myasthenia Gravis: Inside the MINT Trial and CD19 B-Cell Therapy Advances
Get summaries like this every morning.
Free AI-powered recaps of NeuroFrontiers and your other favorite podcasts, delivered to your inbox.
Free forever for up to 3 podcasts. No credit card required.